{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:09:51Z","timestamp":1776276591164,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health: Pacific Ovarian Cancer Research Consortium","award":["NCI P50 CA083636"],"award-info":[{"award-number":["NCI P50 CA083636"]}]},{"name":"National Institutes of Health: Pacific Ovarian Cancer Research Consortium","award":["R21 CA156021"],"award-info":[{"award-number":["R21 CA156021"]}]},{"name":"National Institutes of Health: Pacific Ovarian Cancer Research Consortium","award":["U01 CA152990"],"award-info":[{"award-number":["U01 CA152990"]}]},{"name":"Miriam and Sheldon G. Adelson Medical Research Foundation Grant"},{"name":"American Cancer Society Early Detection Professorship","award":["SIOP-06-258-01-COUN"],"award-info":[{"award-number":["SIOP-06-258-01-COUN"]}]},{"DOI":"10.13039\/100006800","name":"Honorable Tina Brozman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006800","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.ygyno.2015.07.100","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T13:39:24Z","timestamp":1437399564000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma"],"prefix":"10.1016","volume":"139","author":[{"given":"Mari\u00e1n","family":"Novak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Lester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M.","family":"Karst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinita","family":"Parkash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Crum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-6977","authenticated-orcid":false,"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 10","key":"10.1016\/j.ygyno.2015.07.100_bb0005","doi-asserted-by":"crossref","first-page":"x16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3121\/cmr.2007.702","article-title":"Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer","volume":"5","author":"Crum","year":"2007","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0020","doi-asserted-by":"crossref","first-page":"126295","DOI":"10.1155\/2010\/126295","article-title":"Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics","volume":"2010","author":"Gross","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2008.07.018","article-title":"Risk factors for a serous cancer precursor (\u201cp53 signature\u201d) in women with inherited BRCA mutations","volume":"111","author":"Saleemuddin","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.pgp.0000101082.35393.84","article-title":"Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers","volume":"23","author":"Carcangiu","year":"2004","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0040","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0045","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2014evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0055","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ygyno.2014.07.084","article-title":"A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers","volume":"134","author":"Cass","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2013.01.029","article-title":"Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy","volume":"129","author":"Powell","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0065","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/PAS.0b013e31822f58bc","article-title":"Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study","volume":"35","author":"Visvanathan","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/GCO.0000000000000143","article-title":"Clinical management of patients at inherited risk for gynecologic cancer","volume":"27","author":"Powell","year":"2015","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0075","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/PGP.0b013e3181c713a8","article-title":"Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications","volume":"29","author":"Carlson","year":"2010","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2011.05.021","article-title":"Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas","volume":"123","author":"Karst","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0085","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/modpathol.2010.60","article-title":"Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase","volume":"23","author":"Sehdev","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0090","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-2559.2007.02682.x","article-title":"High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour","volume":"50","author":"O'Neill","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2015.07.100_bb0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PGP.0b013e318182c2d2","article-title":"Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma","volume":"28","author":"Phillips","year":"2009","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","article-title":"Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers","volume":"74","author":"Karst","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0105","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0110","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1517\/14728222.2011.620951","article-title":"Stathmin: a protein with many tasks. New biomarker and potential target in cancer","volume":"15","author":"Belletti","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ygyno.2015.07.100_bb0115","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.4161\/cc.10.15.16776","article-title":"The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments","volume":"10","author":"Witkiewicz","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ygyno.2015.07.100_bb0120","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/path.4417","article-title":"The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium","volume":"234","author":"Ning","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200201000-00007","article-title":"p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb","volume":"235","author":"Gerdes","year":"2002","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0130","doi-asserted-by":"crossref","first-page":"a001107","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"Oren","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0135","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/onc.2013.106","article-title":"Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells","volume":"33","author":"Masciarelli","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2015.07.100_bb0140","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0145","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2015.07.100_bb0150","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1073\/pnas.1314302110","article-title":"Synthetic lethality between CCNE1 amplification and loss of BRCA1","volume":"110","author":"Etemadmoghadam","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T16:22:14Z","timestamp":1537460534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815300858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0090825815300858"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.07.100","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.07.100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}